What is HC Wainwright’s Forecast for ZNTL Q3 Earnings?

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) – Analysts at HC Wainwright reduced their Q3 2026 earnings per share estimates for shares of Zentalis Pharmaceuticals in a report released on Friday, August 7th. HC Wainwright analyst A. Maldonado now anticipates that the company will earn ($0.63) per share for the quarter, down from their previous estimate of ($0.57). HC Wainwright currently has a “Buy” rating and a $10.00 price target on the stock. The consensus estimate for Zentalis Pharmaceuticals’ current full-year earnings is ($1.83) per share. HC Wainwright also issued estimates for Zentalis Pharmaceuticals’ Q4 2026 earnings at ($0.66) EPS, FY2026 earnings at ($2.39) EPS, Q1 2027 earnings at ($0.67) EPS, Q2 2027 earnings at ($0.69) EPS, Q3 2027 earnings at ($0.69) EPS, Q4 2027 earnings at ($0.71) EPS, FY2027 earnings at ($2.76) EPS, FY2028 earnings at ($2.13) EPS, FY2029 earnings at ($1.00) EPS and FY2030 earnings at ($0.18) EPS.

Several other brokerages have also commented on ZNTL. Weiss Ratings restated a “sell (d-)” rating on shares of Zentalis Pharmaceuticals in a research note on Monday, July 6th. Mizuho assumed coverage on Zentalis Pharmaceuticals in a research report on Friday, July 17th. They set an “outperform” rating and a $8.00 price objective for the company. Wall Street Zen lowered Zentalis Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Saturday. Finally, Rodman & Renshaw began coverage on Zentalis Pharmaceuticals in a report on Thursday, July 23rd. They set a “buy” rating and a $11.00 price target on the stock. Four research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company has a consensus rating of “Hold” and an average target price of $6.75.

Zentalis Pharmaceuticals Stock Down 1.7%

Shares of NASDAQ:ZNTL opened at $4.15 on Tuesday. The company’s 50-day moving average price is $4.32 and its 200 day moving average price is $3.61. The company has a market cap of $297.43 million, a PE ratio of -2.13 and a beta of 1.92. Zentalis Pharmaceuticals has a fifty-two week low of $1.21 and a fifty-two week high of $6.95.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last released its quarterly earnings data on Thursday, August 6th. The company reported ($0.59) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.49) by ($0.10).

Institutional Investors Weigh In On Zentalis Pharmaceuticals

Several hedge funds have recently made changes to their positions in ZNTL. 5AM Venture Management LLC raised its stake in Zentalis Pharmaceuticals by 705.7% during the 4th quarter. 5AM Venture Management LLC now owns 3,947,913 shares of the company’s stock valued at $5,330,000 after purchasing an additional 3,457,913 shares during the period. BlackRock Inc. purchased a new position in shares of Zentalis Pharmaceuticals during the second quarter valued at $18,205,000. Millennium Management LLC raised its position in Zentalis Pharmaceuticals by 220.6% during the first quarter. Millennium Management LLC now owns 3,069,514 shares of the company’s stock valued at $4,881,000 after buying an additional 2,111,951 shares during the period. Vanguard Group Inc. lifted its stake in Zentalis Pharmaceuticals by 0.7% in the 3rd quarter. Vanguard Group Inc. now owns 2,904,400 shares of the company’s stock worth $4,386,000 after acquiring an additional 19,768 shares in the last quarter. Finally, Renaissance Technologies LLC lifted its stake in Zentalis Pharmaceuticals by 24.0% in the 4th quarter. Renaissance Technologies LLC now owns 2,883,745 shares of the company’s stock worth $3,893,000 after acquiring an additional 558,390 shares in the last quarter.

Key Headlines Impacting Zentalis Pharmaceuticals

Here are the key news stories impacting Zentalis Pharmaceuticals this week:

• Positive Sentiment: HC Wainwright reiterated its Buy rating and $10 price target, substantially above ZNTL’s recent trading level near $4.15. This indicates the firm continues to see meaningful potential upside, likely tied to the company’s oncology pipeline and future clinical or commercial progress.
• Neutral Sentiment: The analyst expects Zentalis to remain unprofitable for several years, with projected losses of $2.39 per share in fiscal 2026 and $2.76 per share in fiscal 2027. Estimates improve thereafter, but the company is still projected to post a $0.18-per-share loss in fiscal 2030.
• Negative Sentiment: HC Wainwright reduced its fiscal 2026 EPS forecast to a loss of $2.39 from $2.19 and lowered its fourth-quarter 2026 estimate to a loss of $0.66 from $0.60. It also cut its fiscal 2027 forecast to a loss of $2.76 from $2.32, suggesting higher expected cash burn or operating expenses.
• Negative Sentiment: Longer-term estimates were also reduced: fiscal 2028 EPS was lowered to a $2.13 loss from $1.80, fiscal 2029 to a $1.00 loss from $0.77, and fiscal 2030 to a $0.18 loss from $0.01. These revisions imply that profitability may arrive later than previously expected.

Zentalis Pharmaceuticals Company Profile

Zentalis Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics for oncology. Leveraging a proprietary structure-based drug discovery platform, the company designs selective inhibitors aimed at critical cancer targets. Zentalis’ research and development efforts center on delivering differentiated therapies that address unmet medical needs in solid tumors and hematologic malignancies.

The company’s lead product candidate, ZN-c3, is an orally administered inhibitor of the p53-MDM2 interaction, currently being evaluated in Phase I clinical trials for advanced solid tumors and hematologic cancers.